文献速递药物不良反应与药物警戒特殊人群用药药物相互作用

文拉法辛相关心血管不良事件的影响因素:FAERS药物警戒分析

Effects of age, sex, daily dose, comorbidity and co-medication on venlafaxine-associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database.
PubMed 文献 · Br J Clin Pharmacol · 2024-10-29

结果显示日剂量与多种心血管事件风险升高相关,高龄、男性、特定合并症及合并喹硫平/氯氮平与心血管事件后死亡相关。

要点

  • 文拉法辛日剂量与心律失常、血栓栓塞、QT延长等心血管事件风险升高相关
  • 高龄(≥75岁)、男性、合并感染/心脏/神经系统疾病及合用喹硫平或氯氮平与心血管事件后死亡相关
  • 常规剂量下心血管死亡风险未见随剂量增加而升高

核心结论

  • 文拉法辛治疗与心血管不良事件相关,日剂量是多种心血管事件的风险因素。
  • 高龄、男性、特定合并症及合并用药与文拉法辛相关心血管事件后死亡相关。

研究设计与样本

  • 采用多因素logistic回归分析年龄、性别、日剂量、合并症及合并用药对心血管事件及死亡的影响。

主要发现

  • 文拉法辛日剂量与心律失常、栓塞和血栓事件、尖端扭转型室速/QT延长、缺血性心脏病、心力衰竭、心肌病及总体心血管事件风险升高相关。
  • 高龄(≥75岁)、男性、合并症(感染和侵染、心脏疾病、神经系统疾病)及合并用药(喹硫平、氯氮平)与文拉法辛相关心血管事件后死亡相关。
  • 心血管死亡风险未随常规文拉法辛剂量增加而升高。

临床怎么用

  • 对高龄(≥75岁)、合并复杂疾病及多重用药的患者使用文拉法辛时应密切监测心血管健康。
  • 关注文拉法辛日剂量与心血管事件风险的关系,尤其对存在心血管基础疾病者。
  • 合用喹硫平或氯氮平的患者需警惕心血管事件后死亡风险。

局限性

  • 本研究为探索性研究,需前瞻性研究验证结果。
  • 基于自发报告数据库,可能存在报告偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aimed to provide a comprehensive view of cardiovascular adverse events (AEs) associated with venlafaxine (VEN) therapy. METHODS: Cardiovascular AE reports for patients receiving VEN therapy were retrieved from January 2004 to December 2023 from the FDA Adverse Event Reporting System database. Effects of age, sex and daily VEN dose on the occurrence of different types of cardiovascular AEs and the influence of demographics, VEN dose, comorbidity and co-medication on death in patients with cardiovascular AEs were analysed by multivariate logistic regression analysis. RESULTS: The study included 16 110 AE reports following VEN treatment (median age: 51 years, females: 69.78%, median VEN daily dose: 100 mg/day). VEN daily dose was associated with increased risks of cardiac arrhythmias, embolic and thrombotic events, torsade de pointes/QT prolongation, ischaemic heart disease, cardiac failure, cardiomyopathy and overall cardiovascular events. The elderly (≥ 75 years), male sex, comorbidity (infections and infestations, cardiac disorders, nervous system disorders) and co-medication (quetiapine and clozapine) were related to death following VEN-associated cardiovascular AEs; however, the risk of cardiovascular death did not increase with regular VEN doses. CONCLUSIONS: Our study confirmed the association of cardiovascular AEs with VEN therapy and revealed the influencing factors for the risk of VEN-related cardiovascular AEs and death due to these events. Based on the obtained evidence, the cardiovascular health of late-elderly patients with complex comorbidity and polytherapy should be closely monitored when they receive VEN therapy. As an exploratory study, prospective studies are needed to validate our findings in the future.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Lu H, Li Y, et al. Effects of age, sex, daily dose, comorbidity and co-medication on venlafaxine-associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database. Br J Clin Pharmacol. 2024. PMID: 39471573. doi:10.1111/bcp.16326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。